Skip to Content

Aeolus Pharmaceuticals Inc AOLS Stock Quote

| Rating as of

PINX:AOLS

Morningstar‘s Stock Analysis AOLS

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics AOLS

Company Profile AOLS

Business Description

Aeolus Pharmaceuticals Inc is a Southern California based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.

Contact
26361 Crown Valley Parkway, Suite 150
Mission Viejo, CA, 92691
T +1 949 481-9825
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Jun 30, 2017
Fiscal Year End Sep 30, 2017
Employees 4